Skip to main content

“The pandemic year of 2020 was exceptional and very challenging for Sartorius Stedim Biotech as well. Our strong business results once again underscore the strength and resilience of our strategy and business model. In this demanding environment, we were able to both achieve very substantial growth and close a few strategically very relevant acquisitions. And more than that: We are an essential contributor toward overcoming this pandemic; each and every day, we deliver essential products and technologies to vaccine manufacturers all over the world.”

Chairman’s Message

Sales revenue


in constant FX: 34.6%

Underlying EBITDA



Order intake


in constant FX: 56.7%




Market capitalization



Group Business Development

Sartorius Stedim Biotech recorded exceptionally dynamic growth in 2020 that was driven by strong organic development, several acquisitions and additional momentum from business related to the coronavirus pandemic. The Group closed the year with significant double-digit growth rates in sales revenue, order intake and earnings, recording further gains across all geographies.

Group Business Development


Sartorius Stedim Biotech expects strong growth for 2021 and beyond. Therefore, with the publication of the 2021 forecast, the company has also considerably raised its mid-term targets for 2025



Sartorius Stedim Biotech plans to grow profitably in 2021 as well. Consolidated sales revenue is thus projected to increase by about 20% to 26%. Regarding profitability, the company forecasts that its underlying EBITDA margin will be about 32.0%, up from 31.7% a year earlier.



Strategy and Long-Term Targets

In view of the strong results in 2020 and the forecasts regarding future organic growth potential, Sartorius Stedim Biotech has raised its mid-term targets. Consolidated sales revenue is expected to rise to about 4 billion euros by 2025 (previous target: around 2.8 billion euros) and the underlying EBITDA margin to around 33% (former guidance: around 30%).